Padcev-Keytruda combination notches another bladder cancer winnews2025-12-17T16:07:05+00:00December 17th, 2025|Endpoints News|
Hansa’s enzyme therapy flunks Phase 3 trial in rare kidney diseasenews2025-12-17T11:20:22+00:00December 17th, 2025|Endpoints News|
DBV charts new path to market peanut allergy patch after Phase 3 successnews2025-12-16T21:12:26+00:00December 16th, 2025|Endpoints News|
Verge Genomics’ ALS drug fails as biotech shifts to partner modelnews2025-12-16T20:04:38+00:00December 16th, 2025|Endpoints News|
Nektar’s immunology drug misses in Phase 2b, execs cite enrollment errorsnews2025-12-16T16:28:59+00:00December 16th, 2025|Endpoints News|
Enhertu combo wins FDA approval for first-line use in metastatic breast cancernews2025-12-15T20:39:58+00:00December 15th, 2025|Endpoints News|
Gilead posts second Phase 3 win for new HIV-fighting drug regimennews2025-12-15T17:47:26+00:00December 15th, 2025|Endpoints News|
Aviceda’s geographic atrophy drug fails mid-stage study. Can it do better in Phase 3?news2025-12-15T16:23:32+00:00December 15th, 2025|Endpoints News|
Palvella unwraps Phase 2 data for rapamycin gel in rare skin diseasenews2025-12-15T16:20:31+00:00December 15th, 2025|Endpoints News|
InnoCare says Zenas-partnered drug succeeds in China study in form of lupusnews2025-12-15T16:15:00+00:00December 15th, 2025|Endpoints News|
